CompletedPhase 1NCT02576496
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Studying Aggressive primary cutaneous T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mundipharma Research Limited
- Principal Investigator
- Pier L Zinzani, MD,PhDUniversity of Bologna Medical Center, Bologna
- Intervention
- Tinostamustine(drug)
- Enrollment
- 106 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2023
Study locations (18)
- Mayo Clinic, Phoenix, Arizona, United States
- Mayo Clinic Cancer Center, Jacksonville, Florida, United States
- Columbia University Medical Center, New York, New York, United States
- University Hospitals Cleveland Seidman Cancer Center, Cleveland, Ohio, United States
- CHU de Caen, Caen, France
- CHU ESTAING Service de thérapie Cellulaire et hématologique Clinique, Clermont-Ferrand, France
- CHU Lille Service des Maladies du Sang, Lille, France
- Hopital Haut Leveque, Pessac, France
- Centre hospitalier Lyon Sud, Pierre-Bénite, France
- University Hospital of Ulm, Department of Internal Medicine III, Ulm, Germany
- Institute of Hematology "L. A. Seràgnoli", University of Bologna, Bologna, Italy
- National Cancer Institute, Fondazione 'G. Pascale', Naples, Italy
- VU medisch centrum, Amsterdam, Netherlands
- Erasmus MC, Rotterdam, Netherlands
- Institut Català d'Oncologia de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02576496 on ClinicalTrials.govOther trials for Aggressive primary cutaneous T-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05544968Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesMedical College of Wisconsin
- RECRUITINGPHASE1NCT07055477A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07047885Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)H. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNANCT06860880Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramUNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07022964CD5 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGNCT07132567Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceKyowa Kirin Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06925464CD7 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGPHASE1NCT06914037A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesTianjin Medical University Cancer Institute and Hospital
See all trials for Aggressive primary cutaneous T-cell lymphoma →